OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
4
Results
Show all
Save search
Copy query
Show results for
Unknown
(3)
Proteomics
(1)
Organisms
Homo sapiens
(1)
Repository
pride
(1)
Tissue
Multiple myeloma cell line
(1)
Plasma cell
(1)
Disease
Multiple myeloma
(1)
Technology Type
Mass Spectrometry
(1)
Shotgun proteomics
(1)
Publication Date
2023
(1)
Release Date
2022
(1)
2021
(1)
2019
(1)
Lab affiliation
Department of Medical Oncology, Dana-Farber Cancer Institute
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Huma Multiple Myeloma Cell line, AMO1, treated with NCP26, LC-MSMS analysis
The human multiple myeloma cell line, AMO1, was treated with NCP26, an ATP-competitive EPRS inhibitor, and a total proteome-wide analysis was performed to determine the effect of NCP26 treatment on protein dynamics.
ORGANISM(S):
Homo sapiens (Human)
2023-03-11
|
PXD029453
|
Pride
Lc-msms
Huma
Ncp26
Multiple myeloma
Cell line
Tmt-labeling
Amo1
Cite
Tracing oncogene-driven remodelling of the intestinal stem cell niche.
Not available
S-EPMC7614896
|
biostudies-literature
Cite
Defining the Identity and Dynamics of Adult Gastric Isthmus Stem Cells.
Not available
S-EPMC6739486
|
biostudies-literature
Cite
Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial.
Not available
S-EPMC9403849
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
